CONCORD BIOTECH Financial Statement Analysis
|
||
|
The Revenues of CONCORD BIOTECH have decreased by -12.10% YoY .
The Earnings Per Share (EPS) of CONCORD BIOTECH has decreased by -29.79 % YoY. |
||
CONCORD BIOTECH Last 5 Annual Financial Results
[BOM: 543960|NSE : CONCORDBIO]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹1,055 Cr | ₹1,200 Cr | ₹1,017 Cr | ₹853 Cr | ₹713 Cr |
| Expenses | ₹687 Cr | ₹693 Cr | ₹585 Cr | ₹505 Cr | ₹439 Cr |
| Operating Profit (Excl OI) | ₹368 Cr | ₹507 Cr | ₹432 Cr | ₹349 Cr | ₹274 Cr |
| Other Income | ₹52 Cr | ₹44 Cr | ₹34 Cr | ₹35 Cr | ₹23 Cr |
| Interest | ₹0.82 Cr | ₹1.04 Cr | ₹3.18 Cr | ₹9.80 Cr | ₹6.14 Cr |
| Depreciation | ₹74 Cr | ₹54 Cr | ₹54 Cr | ₹54 Cr | ₹50 Cr |
| Profit Before Tax | ₹345 Cr | ₹495 Cr | ₹413 Cr | ₹322 Cr | ₹238 Cr |
| Profit After Tax | ₹259 Cr | ₹372 Cr | ₹308 Cr | ₹240 Cr | ₹175 Cr |
| Consolidated Net Profit | ₹261 Cr | ₹372 Cr | ₹308 Cr | ₹240 Cr | ₹175 Cr |
| Earnings Per Share (Rs) | ₹24.94 | ₹35.52 | ₹29.45 | ₹22.95 | ₹183.92 |
| PAT Margin (%) | 24.57 | 30.97 | 30.30 | 28.14 | 24.10 |
| ROE(%) | 13.54 | 22.26 | 21.88 | 20.06 | 16.64 |
| ROCE(%) | 18.04 | 29.62 | 29.13 | 26.70 | 21.66 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.02 | 0.05 |
Key Financials |
||
| Market Cap | : | ₹ 14,866.8 Cr |
| Revenue (TTM) | : | ₹ 1,108.4 Cr |
| Net Profit(TTM) | : | ₹ 270.2 Cr |
| EPS (TTM) | : | ₹ 25.8 |
| P/E (TTM) | : | 55.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CONCORD BIOTECH | 6.9% | 10.7% | -24.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.5% | 2.5% | 14.5% |
| DIVIS LABORATORIES | 7.4% | 22.2% | 26.5% |
| TORRENT PHARMACEUTICALS | 3.1% | 4.3% | 38.5% |
| CIPLA | -1.6% | -1.4% | -6.5% |
| DR REDDYS LABORATORIES | 1.5% | -15.2% | -9.1% |
| MANKIND PHARMA | -5.1% | -3.1% | -2.6% |
| LUPIN | -3% | -4.7% | 21.2% |
| ZYDUS LIFESCIENCES | -0.4% | -2.6% | 14% |
CONCORD BIOTECH Revenues
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | -12.10 % |
| 5 Yr CAGR | 10.29 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,055 Cr | -12.10 | |
| Mar2025 | ₹1,200 Cr | 18.01 | |
| Mar2024 | ₹1,017 Cr | 19.20 | |
| Mar2023 | ₹853 Cr | 19.67 | |
| Mar2022 | ₹713 Cr | - | |
CONCORD BIOTECH Operating Profit
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | -27.41 % |
| 5 Yr CAGR | 7.66 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹368 Cr | -27.41 | |
| Mar2025 | ₹507 Cr | 17.27 | |
| Mar2024 | ₹432 Cr | 23.99 | |
| Mar2023 | ₹349 Cr | 27.25 | |
| Mar2022 | ₹274 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -17.40 % |
| 5 Yr CAGR | -2.39 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 34.88% | -17.40 | |
| Mar2025 | 42.23% | -0.64 | |
| Mar2024 | 42.5% | 4.01 | |
| Mar2023 | 40.86% | 6.35 | |
| Mar2022 | 38.42% | - | |
CONCORD BIOTECH Profit After Tax
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | -29.80 % |
| 5 Yr CAGR | 10.51 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹261 Cr | -29.80 | |
| Mar2025 | ₹372 Cr | 20.62 | |
| Mar2024 | ₹308 Cr | 28.33 | |
| Mar2023 | ₹240 Cr | 37.25 | |
| Mar2022 | ₹175 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -20.67 % |
| 5 Yr CAGR | 0.48 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 24.57 % | -20.67 | |
| Mar2025 | 30.97 % | 2.21 | |
| Mar2024 | 30.3 % | 7.68 | |
| Mar2023 | 28.14 % | 16.76 | |
| Mar2022 | 24.1 % | - | |
CONCORD BIOTECH Earnings Per Share (EPS)
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | -29.79 % |
| 5 Yr CAGR | -39.32 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹25 | -29.79 | |
| Mar2025 | ₹36 | 20.61 | |
| Mar2024 | ₹29 | 28.32 | |
| Mar2023 | ₹23 | -87.52 | |
| Mar2022 | ₹184 | - | |
CONCORD BIOTECH Return on Capital Employed (ROCE)
[BOM: 543960|NSE : CONCORDBIO]
| Y-o-Y | -39.10 % |
| 5 Yr CAGR | -4.47 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 18.04% | -39.10 | |
| Mar2025 | 29.62% | 1.68 | |
| Mar2024 | 29.13% | 9.10 | |
| Mar2023 | 26.7% | 23.27 | |
| Mar2022 | 21.66% | - | |
CONCORD BIOTECH Share Price vs Sensex
| Current Share Price | : | ₹1,421.3 |
| Current MarketCap | : | ₹ 14,866.8 Cr |
| Updated EOD on | : | Aug 04,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD BIOTECH | 6.9% |
10.7% |
-24.4% |
| SENSEX | 2.2% |
0.9% |
-3.7% |
CONCORD BIOTECH related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 250 SMALLCAP INDEX | 2.7% | 0.7% | 3% |
| BSE 1000 | 2.2% | 1.4% | 2.6% |
| BSE 500 | 2.2% | 1.4% | 2.2% |
| BSE 400 MIDSMALLCAP INDEX | 2% | 1.7% | 5.9% |
| BSE HEALTHCARE | 1.2% | 1.4% | 12% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 SHARIAH | 3% | 3.7% | 1.4% |
| NIFTY SMALLCAP 500 | 2.6% | 1.1% | NA |
| NIFTY SMALLCAP 250 | 2.6% | 1.1% | 4.7% |
| NIFTY TOTAL MARKET | 2.5% | 1.7% | 3.1% |
| NIFTY 500 | 2.5% | 1.7% | 2.9% |
You may also like the below Video Courses
FAQ about CONCORD BIOTECH Financials
How the annual revenues of CONCORD BIOTECH have changed ?
The Revenues of CONCORD BIOTECH have decreased by -12.10% YoY .
How the Earnings per Share (EPS) of CONCORD BIOTECH have changed?
The Earnings Per Share (EPS) of CONCORD BIOTECH has decreased by -29.79 % YoY .
Check out Intrinsic Value of Peers of CONCORD BIOTECH
Compare Stock Analytics of Peers of CONCORD BIOTECH
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
